Nitric oxide role in heart failure: Pathophysiology and treatment: Introduction

Journal of Cardiac Failure

Volumn 9, Issue 5 SUPPL. 3, 2003, Pages

  Cohn, Jay N ^a   Loscalzo, Joseph ^b   Franciosa, Joseph A ^c,d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Apartment M 17 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; COLLAGEN; HYDRALAZINE; ISOSORBIDE DINITRATE; NITRIC OXIDE; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

APOPTOSIS; CARDIOVASCULAR SYSTEM; CONFERENCE PAPER; CONTINUING EDUCATION; DRUG INHIBITION; HEART EJECTION FRACTION; HEART FAILURE; HEART VENTRICLE REMODELING; HUMAN; LIFE EXPECTANCY; MUSCLE CELL; NECROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SARCOMERE; SYSTOLE; AFRICAN AMERICAN; CONGESTIVE HEART FAILURE; DRUG EFFECT; EDITORIAL; ETHNOLOGY; METABOLISM; PHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; AFRICAN AMERICANS; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HEART FAILURE, CONGESTIVE; HUMANS; NITRIC OXIDE; VENTRICULAR REMODELING;

EID: 23244462266     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1054/S1071-9164(03)00587-6     Document Type: Conference Paper

References (11)

1. Loscalzo J, Welch G. Nitric oxide and the cardiovascular system. Prog Cardiovasc Dis 1995;38:87-104.
2. Kahn DF, Duffy SJ, Tomasian D, Holbrook M, Rescorl L, Russell J, et al. Effects of black race on forearm resistance vessel function. Hypertension 2002;40:195-201.
3. Cohn JN. Is there a common mechanism of benefit for effective treatment of heart failure? Editorial. Eur J Heart Fail 1999;1:31-4.
4. Cohn JN, Ferrari R, Sharpe N, on Behalf of an International Forum on Cardiac Remodeling. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000;35:569-82.
5. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994;330:1431-8.
6. Sharma R, Davidoff MN. Oxidative stress and endothelial dysfunction in heart failure. Congest Heart Fail 2002;8:165-72.
7. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-7.
8. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure Trials. J Card Fail 1999;5:178-87.
9. Franciosa JA, Taylor AL, Cohn JN, Yancy CW, Ziesche S, Olukotun A et al., for The A-HeFT Investigators African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail 2002; 8:128-35.
10. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
11. Campbell DJ, Aggarwal A, Esler M, Kaye D. Beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet 2001; 358:1609-10.